Mail-in self-collection tests for human papillomavirus more than doubled cervical cancer screening participation among never- and under-screened U.S. women, according to a first-of-its-kind study from researchers at the University of Texas MD Anderson Cancer Center.
Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins—molecules that transport fat in blood—which enriches cancer cells with an antioxidant shield to survive stress, according to new research from Children’s Medical Center Research Institute at UT Southwestern published in Nature.
A genetic mutation that fuses two genes drives several cancer types by forming networks of protein interactions that alter gene expression in cells, a study by UT Southwestern Medical Center researchers suggests.
The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.
First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.
Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.
Patients with colon cancer who consumed an anti-inflammatory diet during a phase III clinical trial showed longer overall survival post-treatment, compared to those on a proinflammatory diet, according to a Dana-Farber Cancer Institute analysis.
Researchers from UC Davis Comprehensive Cancer Center is testing a drug called niraparib (Zejula), given before prostate cancer surgery. Researchers think it could enable more personalized treatments—especially for men with prostate cancer that has specific DNA repair gene mutations.
A new targeted cancer drug, DB-1310, is showing early signs of effectiveness in patients with advanced solid tumors that have not responded to standard treatments, particularly those with EGFR-mutant non-small cell lung cancer, according to results from an international clinical trial led by Aaron Lisberg at the UCLA Health Jonsson Comprehensive Cancer Center.
A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer.
